Skip to main content
Heidelberg Pharma AG logo

Heidelberg Pharma AG — Investor Relations & Filings

Ticker · HPHA ISIN · DE000A11QVV0 LEI · 391200E09XYBYITR1W32 F Manufacturing
Open in API
Filings indexed 806 across all filing types
Latest filing 2022-12-16 Regulatory Filings
Country DE Germany
Listing F HPHA

About Heidelberg Pharma AG

https://heidelberg-pharma.com/en/

Heidelberg Pharma AG is a clinical-stage biopharmaceutical company specializing in the development of targeted cancer therapies. The company's core focus is its proprietary Antibody-Drug Conjugate (ADC) technology platform, which utilizes the toxin Amanitin. This platform, known as Antibody Targeted Amanitin Conjugates (ATACs®), is designed to deliver the highly potent Amanitin payload directly to tumor cells. Heidelberg Pharma is the first company to advance Amanitin into clinical development for cancer treatment. Its lead candidate, HDP-101, is in clinical trials for patients with multiple myeloma. The company leverages its ADC expertise to create novel medicines for oncology.

Recent filings

Filing Released Lang Actions
Heidelberg Pharma Signs Research and Exclusive Option Agreement with Binghamton University on Immunostimulatory Technology Platform
Regulatory Filings Classification · 100% confidence The document is a press release dated December 16, 2022, announcing a 'Research and Exclusive Option Agreement' between Heidelberg Pharma AG and Binghamton University regarding a technology platform. It details a strategic partnership and potential future licensing, which falls under corporate development or alliance news. It is not a formal regulatory filing like a 10-K, an earnings release (ER), or a quarterly report (IR). Since it is a specific announcement about a corporate agreement/alliance, the most fitting category among the provided options is not explicitly 'Alliance' or 'Partnership'. However, it is a significant corporate event announcement. Given the options, this type of announcement, which details strategic corporate activity but isn't a standard financial report or insider trade, often defaults to a general regulatory announcement or news release category. Since it is a specific news item about a strategic agreement, and not a standard financial report, it is best classified as a general Regulatory Filing (RNS) as a catch-all for significant, non-standard corporate news, or potentially a Capital/Financing Update (CAP) if the agreement involved immediate capital structuring, but the text focuses on research and option rights, not immediate financing. Given the nature of the announcement (a corporate partnership/alliance), and lacking a specific 'Alliance' code, RNS (Regulatory Filings / General Regulatory Announcements) is the most appropriate fallback for this type of news release.
2022-12-16 English
Heidelberg Pharma AG: Encouraging Clinical Data from Two Antibody Drug Conjugates Based on Heidelberg Pharmas ATAC Technology Presented at the ASH Annual Meeting 2022
Earnings Release Classification · 99% confidence The document is a press release dated December 14, 2022, announcing that initial clinical data from two Antibody Drug Conjugates (ADCs) based on Heidelberg Pharma's ATAC technology were presented at the ASH Annual Meeting 2022. It details preliminary safety and efficacy data for HDP-101 and MGTA-117. This content is a corporate update regarding clinical trial progress and scientific presentation, not a formal regulatory filing like a 10-K, an earnings release (ER), or a comprehensive interim report (IR). Since it is a specific announcement about scientific/clinical progress, it fits best under the general 'Regulatory Filings' (RNS) category as a miscellaneous corporate news item, as there is no specific code for 'Clinical Data Presentation Announcement'. It is not short enough to be a simple RPA, as it contains substantial detail about the trial results and technology. Q4 2022
2022-12-14 English
Heidelberg Pharma and Partner Magenta to Present Initial Clinical Data on their Antibody Drug Conjugates at the ASH Annual Meeting 2022
Regulatory Filings Classification · 99% confidence The document is a press release disseminated via EQS News, dated November 10, 2022. It announces that Heidelberg Pharma and its partner Magenta will present initial clinical data (related to Antibody Drug Conjugates) at the ASH Annual Meeting 2022. This is not a full financial report (like 10-K or IR), nor is it a formal regulatory filing like a Director's Dealing or Major Shareholding Notification. It is an announcement about participation in a scientific/investor conference and the data to be presented. This fits best under the category of general corporate news or an announcement related to investor relations/presentations, but since it is specifically announcing participation and presentation of data at a major industry meeting, it is most closely aligned with Investor Presentation (IP) content being announced, or potentially a Regulatory Filing (RNS) if it were a general announcement. However, given the content focuses on clinical data presentation at a conference, it is a form of corporate communication intended for investors and the public. Since it is an announcement about presenting data, and not the presentation itself, and it is not a standard financial report, the most appropriate classification among the choices is often the general regulatory/news category (RNS) or potentially a specific investor-focused announcement if one existed. Given the options, and recognizing this is a standard corporate news release announcing scientific updates, RNS (Regulatory Filings / General Regulatory Announcements) is the most suitable fallback for non-standard, time-sensitive corporate news that isn't a core financial report or specific transaction notice. It is not an Earnings Release (ER) as it discusses clinical trial data, not financial performance highlights.
2022-11-10 English
Heidelberg Pharmas Partner Telix Reports Positive Data on the Pivotal ZIRCON Study
Regulatory Filings Classification · 99% confidence The document is a press release dated November 7, 2022, announcing positive top-line data from the pivotal ZIRCON Phase III study conducted by Telix Pharmaceuticals, a partner of Heidelberg Pharma AG, regarding the imaging agent TLX250-CDx for renal cancer. It details study endpoints, sensitivity/specificity results, and future regulatory filing intentions (BLA with the FDA). This content is a corporate update announcing significant clinical trial results and strategic next steps, which aligns best with an Earnings Release (ER) if it were quarterly results, but since it is a specific clinical/partner update, it functions as a major corporate announcement. Given the options, it is a significant corporate news item. It is not a full 10-K, AR, or IR. It is not a transcript (CT) or a formal proxy/governance document. It is a news announcement about clinical progress and partnership milestones. This type of announcement, focusing on key results and future regulatory plans, is most closely categorized as an Earnings Release (ER) in function (announcing key performance indicators/results), or potentially a Regulatory Filing (RNS) if it were a mandatory filing, but ER captures the 'results announcement' nature better than RNS, which is a fallback. However, since it is not explicitly quarterly earnings, and is a specific partnership/clinical update, it fits the general category of a significant corporate announcement. Given the provided definitions, and noting that it is a 'PRESS RELEASE' detailing key performance data (study results), it functions similarly to an ER, but since it is not explicitly financial results for a reporting period, RNS (Regulatory Filings/General Announcement) is the safest fallback for non-standard, material news, or we must check if it fits better elsewhere. It is not a management report (MDA) which explains financial results. It is a material announcement of clinical success. In many databases, major clinical trial updates are classified under 'Press Release' or 'Material Event'. Since 'ER' is defined as 'Initial announcement of quarterly/periodical financial results (key highlights only)', and this is clinical data, RNS is the most appropriate catch-all for material, non-standard announcements.
2022-11-07 English
EQS-DD: Heidelberg Pharma AG english
Director's Dealing Classification · 100% confidence The document is explicitly titled 'Directors’ Dealings' and contains detailed information regarding a transaction involving a 'person closely associated' with a member of the administrative body (Dr. Mathias Hothum). It specifies the nature of the transaction (Sale), the price, volume, and date, which are the core components of an insider trading or director's dealing disclosure. This directly maps to the 'Director's Dealing' definition.
2022-10-13 English
EQS-DD: Heidelberg Pharma AG english
Director's Dealing Classification · 100% confidence The document is explicitly titled 'Directors’ Dealings' and contains a section detailing 'Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them'. It lists the name of the associated person (Dr. Friedrich von Bohlen), their position, and details of a transaction (Sale) involving shares, including price and volume. This directly matches the definition for Director's Dealing (DIRS). The document length is short (2343 chars), but it is the primary disclosure itself, not an announcement of a separate report.
2022-10-13 English

Browse filings by year

21 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.